<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37783406</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7573</ISSN><JournalIssue CitedMedium="Internet"><Volume>319</Volume><Issue>Pt 2</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of ethnopharmacology</Title><ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation></Journal><ArticleTitle>Molecular networking unveils anti-SARS-CoV-2 constituents from traditionally used remedies.</ArticleTitle><Pagination><StartPage>117206</StartPage><MedlinePgn>117206</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2023.117206</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0378-8741(23)01076-0</ELocationID><Abstract><AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Plants and fungi have a long tradition in ethnopharmacology for the treatment of infectious diseases including viruses. Many of these natural products have also been used to combat SARS-CoV-2 infections or symptoms of the post- and long-COVID form, owing to the scarcity of clinically approved therapeutics.</AbstractText><AbstractText Label="AIM OF THE STUDY" NlmCategory="OBJECTIVE">The ongoing threat posed by SARS-CoV-2, along with the rapidly evolving new variants, requires the development of new antiviral compounds. The aim of this study was to identify anti-SARS-CoV-2 herbal and fungal extracts used in traditional medicine against acute respiratory infection, inflammation, and related symptoms. Additionally, we sought to characterize their bioactive constituents.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The antiviral activity and cell cytotoxicity of 179 herbal and fungal extracts were evaluated using two SARS-CoV-2 infection assays in Caco-2&#xa0;cells. 19 plant extracts with and without anti-SARS-CoV-2 activity underwent detailed dereplication using molecular networking.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Extracts from Angelica sinensis (Oliv.) Diels roots, Annona squamosa L. seeds, Azadirachta indica A. Juss. fruits, Buddleja officinalis Maxim. flowers, Burkea africana Hook. bark and Clinopodium menthifolium (Host) Stace aerial parts showed a potent anti SARS-CoV-2 activity (IC<sub>50</sub>&#xa0;&lt;&#xa0;5&#xa0;&#x3bc;g/ml) with only moderate cytotoxicity (CC<sub>50</sub>&#xa0;&gt;&#xa0;60&#xa0;&#x3bc;g/ml, Caco-2). By performing the dereplication with a bioactivity-featured molecular network (MN) on the extract library level, rather than on the level of individual extracts, we could pinpoint compounds characteristic for active extracts. Thus, a straight-forward identification of potential anti-SARS-CoV-2 natural compounds was achieved prior to any fractionation or isolation efforts.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A sophisticated hyphenation of empirical knowledge with MS-based bioinformatics and automated compound annotation was applied to decipher the chemical space of the investigated extracts. The correlation with experimentally assessed anti-SARS-CoV-2 activities helped in predicting compound classes and structural elements relevant for the antiviral activities. Consequently, this accelerated the identification of constituents from the investigated mixtures with inhibitory effects against SARS-CoV-2.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wasilewicz</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Division of Pharmacognosy, University of Vienna, Josef-Holaubek-Platz 2, 1090, Vienna, Austria; Vienna Doctoral School of Pharmaceutical, and Sport Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090, Vienna, Austria. Electronic address: andreas.wasilewicz@univie.ac.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bojkova</LastName><ForeName>Denisa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Medical Virology, University Hospital Frankfurt, Paul-Ehrlich-Stra&#x3b2;e 40, 60596, Frankfurt am Main, Germany. Electronic address: denisa.bojkova@kgu.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beniddir</LastName><ForeName>Mehdi A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>&#xc9;quipe Chimie des Substances Naturelles, BioCIS, CNRS, Universit&#xe9; Paris-Saclay, 17 Avenue des Sciences, 91400, Orsay, France. Electronic address: mehdi.beniddir@universite-paris-saclay.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cinatl</LastName><ForeName>Jindrich</ForeName><Initials>J</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Institute of Medical Virology, University Hospital Frankfurt, Paul-Ehrlich-Stra&#x3b2;e 40, 60596, Frankfurt am Main, Germany. Electronic address: cinatl@em.uni-frankfurt.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabenau</LastName><ForeName>Holger F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Institute of Medical Virology, University Hospital Frankfurt, Paul-Ehrlich-Stra&#x3b2;e 40, 60596, Frankfurt am Main, Germany. Electronic address: rabenau@em.uni-frankfurt.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grienke</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Division of Pharmacognosy, University of Vienna, Josef-Holaubek-Platz 2, 1090, Vienna, Austria. Electronic address: ulrike.grienke@univie.ac.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rollinger</LastName><ForeName>Judith M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Division of Pharmacognosy, University of Vienna, Josef-Holaubek-Platz 2, 1090, Vienna, Austria. Electronic address: judith.rollinger@univie.ac.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirchweger</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Division of Pharmacognosy, University of Vienna, Josef-Holaubek-Platz 2, 1090, Vienna, Austria. Electronic address: benjamin.kirchweger@univie.ac.at.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>J Ethnopharmacol</MedlineTA><NlmUniqueID>7903310</NlmUniqueID><ISSNLinking>0378-8741</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018938" MajorTopicYN="N">Caco-2 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37783406</ArticleId><ArticleId IdType="doi">10.1016/j.jep.2023.117206</ArticleId><ArticleId IdType="pii">S0378-8741(23)01076-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>